- Home
- TLSI vs CRVO Comparison
TLSI vs CRVO Comparison
Compare TLSI & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- CRVO
- Stock Information
- Founded
- TLSI 2010
- CRVO 2001
- Country
- TLSI United States
- CRVO United States
- Employees
- TLSI N/A
- CRVO N/A
- Industry
- TLSI Medical Specialities
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- CRVO Health Care
- Exchange
- TLSI Nasdaq
- CRVO Nasdaq
- Market Cap
- TLSI 124.9M
- CRVO 98.3M
- IPO Year
- TLSI N/A
- CRVO N/A
- Fundamental
- Price
- TLSI $4.69
- CRVO $2.13
- Analyst Decision
- TLSI Strong Buy
- CRVO Buy
- Analyst Count
- TLSI 6
- CRVO 8
- Target Price
- TLSI $11.75
- CRVO $38.75
- AVG Volume (30 Days)
- TLSI 36.4K
- CRVO 476.7K
- Earning Date
- TLSI 11-14-2024
- CRVO 11-12-2024
- Dividend Yield
- TLSI N/A
- CRVO N/A
- EPS Growth
- TLSI N/A
- CRVO N/A
- EPS
- TLSI N/A
- CRVO N/A
- Revenue
- TLSI $26,891,000.00
- CRVO $10,066,550.00
- Revenue This Year
- TLSI $60.96
- CRVO $34.17
- Revenue Next Year
- TLSI $53.65
- CRVO N/A
- P/E Ratio
- TLSI N/A
- CRVO N/A
- Revenue Growth
- TLSI 67.90
- CRVO 116.29
- 52 Week Low
- TLSI $3.50
- CRVO $1.80
- 52 Week High
- TLSI $10.42
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- TLSI 51.68
- CRVO 28.45
- Support Level
- TLSI $4.72
- CRVO $1.99
- Resistance Level
- TLSI $5.32
- CRVO $2.43
- Average True Range (ATR)
- TLSI 0.31
- CRVO 0.17
- MACD
- TLSI 0.01
- CRVO 0.31
- Stochastic Oscillator
- TLSI 47.52
- CRVO 26.92
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.